111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
银屑病与肠道菌群失调的临床治疗及临床应用研究进展
Authors Zhao N, Wang K, Jiang Y, Huang R
Received 11 August 2025
Accepted for publication 6 November 2025
Published 24 November 2025 Volume 2025:18 Pages 3155—3164
DOI https://doi.org/10.2147/CCID.S559957
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Michela Starace
Nana Zhao,1,2,* Kejia Wang,1,* Yangzhi Jiang,1 Rongzhong Huang2
1Department of Geriatric Medicine, The Seventh People’s Hospital of Chongqing/The Central Hospital Affiliated to Chongqing University of Technology, Chongqing, People’s Republic of China; 2Precision Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Rongzhong Huang, Email rzhuang@live.com
Abstract: Psoriasis is a prevalent chronic inflammatory dermatosis. Recent evidence indicates a significant association between gut microbiota dysbiosis and its pathogenesis, potentially mediated through immunoinflammatory modulation and skin barrier integrity. This article systematically reviews the mechanisms linking gut microbiota to psoriasis, with emphasis on clinical treatment strategies targeting microbiota modulation—including probiotics, fecal microbiota transplantation (FMT), dietary interventions, and antibiotic therapies. However, current research exhibits notable limitations: most evidence derives from small-scale studies or animal models, lacking validation via large-scale clinical trials; microbiota-targeted interventions are poorly standardized, and the impact of individual variability on therapeutic outcomes remains unclear; the long-term safety of antibiotics and FMT requires further assessment. While summarizing existing advances, this review presents an evaluative overview to highlight research gaps and proposes future directions, such as integrated multi-omics studies, development of standardized therapeutic protocols, and exploration of personalized microbiota-based strategies, to innovate clinical management of psoriasis.
Keywords: psoriasis, gut microbiota, clinical treatment, probiotics, fecal microbiota transplantation
1Department of Geriatric Medicine, The Seventh People’s Hospital of Chongqing/The Central Hospital Affiliated to Chongqing University of Technology, Chongqing, People’s Republic of China; 2Precision Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Rongzhong Huang, Email rzhuang@live.com
Abstract: Psoriasis is a prevalent chronic inflammatory dermatosis. Recent evidence indicates a significant association between gut microbiota dysbiosis and its pathogenesis, potentially mediated through immunoinflammatory modulation and skin barrier integrity. This article systematically reviews the mechanisms linking gut microbiota to psoriasis, with emphasis on clinical treatment strategies targeting microbiota modulation—including probiotics, fecal microbiota transplantation (FMT), dietary interventions, and antibiotic therapies. However, current research exhibits notable limitations: most evidence derives from small-scale studies or animal models, lacking validation via large-scale clinical trials; microbiota-targeted interventions are poorly standardized, and the impact of individual variability on therapeutic outcomes remains unclear; the long-term safety of antibiotics and FMT requires further assessment. While summarizing existing advances, this review presents an evaluative overview to highlight research gaps and proposes future directions, such as integrated multi-omics studies, development of standardized therapeutic protocols, and exploration of personalized microbiota-based strategies, to innovate clinical management of psoriasis.
Keywords: psoriasis, gut microbiota, clinical treatment, probiotics, fecal microbiota transplantation